Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Various

Cancer; thrombosis

Plasminogen activator inhibitor 1 (SERPINE1; PAI1)

In vitro and mouse studies suggest enhancing the interaction of PAI1 with the N-terminal region of prolactin (PRL) could help inhibit angiogenesis and treat thrombosis or cancer. In human endothelial cells, the N-terminal region of prolactin, 16K PRL, bound the angiogenesis promoter PAI1. In mice implanted with murine melanoma or mammary cancer cells, 16K PRL decreased angiogenesis and tumor growth compared with vehicle. In a mouse model of systemic thrombosis, 16K PRL increased survival compared with vehicle. Next steps could include studies in additional models of thrombosis-related diseases.
IMMD Inc. has IMD-4852, a PAI1 inhibitor, in preclinical development to treat thrombosis.

SciBX 7(28); doi:10.1038/scibx.2014.838
Published online July 24, 2014

Patent application filed; available for licensing for thrombosis-related diseases

Bajou, K. et al. Nat. Med.; published online June 15, 2014;
doi:10.1038/nm.3552
Contact: Ingrid Struman, University of Liège, Liège, Belgium
e-mail:

i.struman@ulg.ac.be